

LANDEC CORP \CA\
Form 10-Q
April 07, 2017

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the Fiscal Quarter Ended February 26, 2017, or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the transition period from _____ to _____.

Commission file number: **0-27446**

LANDEC CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

94-3025618

(IRS Employer Identification Number)

3603 Haven Avenue

Menlo Park, California 94025

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code:

(650) 306-1650

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the past 90 days.

Yes X No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes X No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "large accelerated filer" and "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer Accelerated Filer X
Non Accelerated Filer Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No X

As of March 31, 2017, there were 27,305,179 shares of Common Stock outstanding.

LANDEC CORPORATION

FORM 10-Q

For the Fiscal Quarter Ended February 26, 2017

INDEX

	Page
Facing sheet	
Index	i
Part I. Financial Information	
Item 1. Financial Statements	
a) Consolidated Balance Sheets as of February 26, 2017 and May 29, 2016	1
b) Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended February 26, 2017 and February 28, 2016	2
c) Consolidated Statements of Changes in Stockholders' Equity for the Nine Months Ended February 26, 2017	3
d) Consolidated Statements of Cash Flows for the Nine Months Ended February 26, 2017 and February 28, 2016	4
e) Notes to Consolidated Financial Statements	5
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3. Quantitative and Qualitative Disclosures About Market Risk	27
Item 4. Controls and Procedures	27
Part II. Other Information	28
Item 1. Legal Proceedings	28

Item 1A.	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosures	28
Item 5.	Other Information	28
Item 6.	Exhibits	29
	Signatures	30

PART I. FINANCIAL INFORMATION**Item 1. Financial Statements****LANDEC CORPORATION****CONSOLIDATED BALANCE SHEETS****(In thousands except par value)**

	February 26, 2017 (unaudited)	May 29, 2016 As Adjusted (1)
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 12,734	\$9,894
Accounts receivable, less allowance for doubtful accounts	45,918	46,406
Inventories	23,273	25,535
Prepaid expenses and other current assets	4,650	4,468
Total Current Assets	86,575	86,303
Investment in non-public company, fair value	63,400	62,700
Property and equipment, net	123,005	120,880
Goodwill, net	49,620	49,620
Trademarks/tradenames, net	14,428	14,428
Customer relationships, net	6,304	6,968
Other assets	2,804	1,754
Total Assets	\$ 346,136	\$ 342,653
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current Liabilities:		
Accounts payable	\$ 24,764	\$ 30,904
Accrued compensation	6,136	5,460
Other accrued liabilities	10,904	7,772
Deferred revenue	429	832
Line of credit	—	3,500
Current portion of long-term debt, net	4,940	7,873
Total Current Liabilities	47,173	56,341
Long-term debt, net	43,534	45,972
Capital lease obligation, less current portion	3,751	3,804
Deferred taxes, net	25,507	22,442

Other non-current liabilities	2,031	1,744
Total Liabilities	121,996	130,303
Stockholders' Equity:		
Common stock, \$0.001 par value; 50,000 shares authorized; 27,305 and 27,148 shares issued and outstanding at February 26, 2017 and May 29, 2016, respectively	27	27
Additional paid-in capital	140,134	137,244
Retained earnings	82,018	73,457
Accumulated other comprehensive income	430	—
Total Stockholders' Equity	222,609	210,728
Non-controlling interest	1,531	1,622
Total Equity	224,140	212,350
Total Liabilities and Stockholders' Equity	\$ 346,136	\$ 342,653

(1) Derived from audited financial statements. See Note 1 – Organization, Basis of Presentation, and Summary of Significant Accounting Policies for discussion of accounting guidance adopted during the period.

See accompanying notes.

LANDEC CORPORATION**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME****(Unaudited)****(In thousands, except per share amounts)**

	Three Months Ended		Nine Months Ended	
	February	February	February	February
	26,	28,	26,	28,
	2017	2016	2017	2016
Product sales	\$136,568	\$129,990	\$404,827	\$405,786
Cost of product sales	113,136	117,059	341,298	357,613
Gross profit	23,432	12,931	63,529	48,173
Operating expenses:				
Research and development	2,014	1,895	5,917	5,413
Selling, general and administrative	15,009	10,659	41,969	35,638
Legal settlement charge	2,080	—	2,580	—
Impairment of GreenLine tradename	—	34,000	—	34,000
Total operating costs and expenses	19,103	46,554	50,466	75,051
Operating income (loss)	4,329	(33,623)	13,063	(26,878)
Dividend income	413	413	1,238	1,238
Interest income	8	17	15	64
Interest expense, net	(400)	(484)	(1,432)	(1,425)
Loss on debt refinancing	—	—	(1,233)	—
Other income	700	—	700	1,000
Net income (loss) before taxes	5,050	(33,677)	12,351	(26,001)
Income tax (expense) benefit	(1,556)	12,510	(4,138)	9,750
Consolidated net income (loss)	3,494	(21,167)	8,213	(16,251)
Non-controlling interest income (expense)	6	(23)	(75)	(119)
Net income (loss) and comprehensive income applicable to common stockholders	\$3,500	\$(21,190)	\$8,138	\$(16,370)
Basic net income (loss) per share	\$0.13	\$(0.78)	\$0.30	\$(0.61)
Diluted net income (loss) per share	\$0.13	\$(0.78)	\$0.29	\$(0.61)
Shares used in per share computation				
Basic	27,286	27,054	27,252	27,026
Diluted	27,682	27,054	27,608	27,026

Other comprehensive income, net of tax:

Edgar Filing: LANDEC CORP \CA\ - Form 10-Q

Change in net unrealized gains on interest rate swap (net of tax effect of \$59, \$0, \$251, and \$0)	\$ 103	\$—	\$430	\$—
Other comprehensive income, net of tax	103	—	430	—
Total comprehensive income (loss)	\$3,603	\$(21,190)	\$8,568	\$(16,370)

See accompanying notes.

LANDEC CORPORATION**CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY****(Unaudited)****(in thousands, except per share amounts)**

	Common Stock		Additional Paid-in	Retained	Accumulated Other Comprehensive Income	Total Stockholders' controlling	Non- Interest
	Shares	Amount	Capital	Earnings		Equity	
Balance at May 29, 2016	27,148	\$ 27	\$ 137,244	\$ 73,457	\$ —	\$ 210,728	\$ 1,622
Cumulative-effect adjustment - ASU 2016-09 adoption (1)	—	—	200	423	—	623	—
Issuance of common stock at \$5.63 to \$6.66 per share, net of taxes paid by Landec on behalf of employees	86	—	233	—	—	233	—
Issuance of common stock for vested restricted stock units ("RSUs")	71	—	—	—	—	—	—
Taxes paid by Company for stock swaps and RSUs	—	—	(385)	—	—	(385)	—
Stock-based compensation	—	—	2,842	—	—	2,842	—
Payments to non-controlling interest	—	—	—	—	—	—	(166)
Net income	—	—	—	8,138	—	8,138	75
Other comprehensive income, net of tax	—	—	—	—	430	430	—
Balance at February 26, 2017	27,305	\$ 27	\$ 140,134	\$ 82,018	\$ 430	\$ 222,609	\$ 1,531

(1) See Note 1 – Organization, Basis of Presentation, and Summary of Significant Accounting Policies for a discussion of accounting guidance adopted during the period.

See accompanying notes.

LANDEC CORPORATION**Consolidated Statements of Cash Flows****(Unaudited)****(In thousands)**

	Nine Months Ended	
	February 26,	February 28,
	2017	2016
		As Adjusted (1)
Cash flows from operating activities:		
Consolidated net income (loss)	\$8,213	\$(16,251)
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	7,827	6,486
Stock-based compensation expense	2,842	2,581
Deferred taxes	3,437	(10,560)
Loss on early debt extinguishment	1,233	—
Change in investment in non-public company, fair value	(700)	(1,000)
Net loss (gain) on disposal of property and equipment	264	(20)
Impairment of GreenLine tradename	—	34,000
Changes in current assets and current liabilities:		
Accounts receivable, net	488	3,555
Inventories	2,262	(2,135)
Prepaid expenses and other current assets	(137)	(14)
Deposit for workers' compensation collateral	(100)	(225)
Accounts payable	(6,140)	(9,918)
Accrued compensation	676	(2,536)
Other accrued liabilities	3,419	2,158
Deferred revenue	(403)	309
Net cash provided by operating activities	23,181	6,430
Cash flows from investing activities:		
Purchases of property and equipment	(9,488)	(26,159)
Deposit on capital lease	—	(850)
Proceeds from sales of fixed assets	74	127
Net cash used in investing activities	(9,414)	(26,882)
Cash flows from financing activities:		
Proceeds from sale of common stock	233	282
Taxes paid by Company for stock swaps and RSUs	(385)	—

Proceeds from long-term debt	50,000	26,748
Payments on long-term debt	(55,966)	(12,150)
Proceeds from lines of credit	1,500	19,500
Payments on lines of credit	(5,000)	(19,500)
Payments for debt issuance costs	(902)	—
Payments for early debt extinguishment penalties	(233)	—
Payments to non-controlling interest	(166)	(248)
Other, net	(8)	(93)
Net cash (used in) provided by financing activities	(10,927)	14,539
Net increase (decrease) in cash and cash equivalents	2,840	(5,913)
Cash and cash equivalents at beginning of period	9,894	14,127
Cash and cash equivalents at end of period	\$ 12,734	\$ 8,214
Supplemental disclosures of noncash investing and financing activities:		
Facility acquired under a capital lease	\$—	\$ 3,775

- (1) See Note 1 – Organization, Basis of Presentation, and Summary of Significant Accounting Policies for a discussion of accounting principles adopted during the period.

See accompanying notes.

LANDEC CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization, Basis of Presentation, and Summary of Significant Accounting Policies

Organization

Landec Corporation and its subsidiaries (“Landec” or the “Company”) design, develop, manufacture, and sell differentiated products for food and biomaterials markets, and license technology applications to partners. The Company has two proprietary polymer technology platforms: 1) Intelimer® polymers, and 2) hyaluronan (“HA”) biopolymers. The Company sells specialty packaged branded Eat Smart® and GreenLine® and private label fresh-cut vegetables and whole produce to retailers, club stores, and foodservice operators, primarily in the United States, Canada, and Asia through its Apio, Inc. (“Apio”) subsidiary, and sells HA-based and non-HA biomaterials through its Lifecore Biomedical, Inc. (“Lifecore”) subsidiary. The Company’s HA biopolymers and non-HA materials are proprietary in that they are specially formulated for specific customers to meet strict regulatory requirements. The Company’s technologies, along with its customer relationships and tradenames, are the foundation, and a key differentiating advantage upon which Landec has built its business.

Basis of Presentation

The accompanying unaudited consolidated financial statements of Landec have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring accruals) have been made which are necessary to present fairly the financial position of the Company at February 26, 2017 and the results of operations and cash flows for all periods presented. Although Landec believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements and related footnotes prepared in accordance with GAAP have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission. The accompanying financial data should be reviewed in conjunction with the audited financial statements and accompanying notes included in Landec's Annual Report on Form 10-K for the fiscal year ended May 29, 2016. Certain prior period data has been reclassified in the consolidated financial statements and accompanying footnotes to conform to current period presentation.

The results of operations for the nine months ended February 26, 2017 are not necessarily indicative of the results that may be expected for an entire fiscal year because there is some seasonality in Apio's food business, particularly, Apio's export business, and the order patterns of Lifecore's customers which may lead to significant fluctuations in Landec's quarterly results of operations.

Basis of Consolidation

The consolidated financial statements are presented on the accrual basis of accounting in accordance with GAAP and include the accounts of Landec Corporation and its subsidiaries, Apio and Lifecore. All intercompany transactions and balances have been eliminated.

Arrangements that are not controlled through voting or similar rights are reviewed under the guidance for variable interest entities ("VIEs"). A company is required to consolidate the assets, liabilities, and operations of a VIE if it is determined to be the primary beneficiary of the VIE.

An entity is a VIE and subject to consolidation, if by design: a) the total equity investment at risk is not sufficient to permit the entity to finance its activities without additional subordinated financial support provided by any party, including equity holders, or b) as a group the holders of the equity investment at risk lack any one of the following three characteristics: (i) the power, through voting rights or similar rights to direct the activities of an entity that most significantly impact the entity's economic performance, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity. The Company reviewed the consolidation guidance and concluded that its partnership interest in Apio Cooling, LP and its equity investment in the non-public company are not VIEs.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management's most significant and subjective judgments include revenue recognition; loss contingencies; sales returns and allowances; self-insurance liabilities; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived assets including intangible assets and inventory; the valuation of investments; and the valuation and recognition of stock-based compensation.

These estimates involve the consideration of complex factors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve and are subject to change from period to period. The actual results may differ from management's estimates.

Cash and Cash Equivalents

The Company records all highly liquid securities with three months or less from date of purchase to maturity as cash equivalents. Cash equivalents consist mainly of money market funds. The market value of cash equivalents approximates their historical cost given their short-term nature.

Debt Issuance Costs

The Company records its line of credit debt issuance costs as an asset, and as such, \$120,000 and \$431,000 was recorded as prepaid expenses and other current assets and other assets, respectively, as of February 26, 2017. The Company records its term debt issuance costs as a contra-liability, and as such, \$60,000 and \$216,000 was recorded as current portion of long-term debt and long-term debt, respectively, as of February 26, 2017. See Note 7 – Debt of the Notes to Consolidated Financial Statements for further information.

Financial Instruments

The Company's financial instruments are primarily composed of commercial-term trade payables, grower advances, notes receivable, and debt instruments. For short-term instruments, the historical carrying amount approximates the fair value of the instrument. The fair value of long-term debt approximates its carrying value.

Cash Flow Hedges

The Company entered into an interest rate swap agreement to manage interest rate risk. This derivative instrument may offset a portion of the changes in interest expense. The Company designates this derivative instrument as a cash flow hedge. The Company accounts for its derivative instrument as either an asset or a liability and carries it at fair value in Other assets or Other non-current liabilities. The accounting for changes in the fair value of the derivative instrument depends on the intended use of the derivative instrument and the resulting designation.

For derivative instruments that hedge the exposure to variability in expected future cash flows that are designated as cash flow hedges, the effective portion of the gain or loss on the derivative instrument is reported as a component of Accumulated Other Comprehensive Income in Stockholders' Equity and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The ineffective portion of the gain or loss on the derivative instrument, if any, is recognized in earnings in the current period. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions.

For additional information refer to Note 10 – Comprehensive Income.

Investment in Non-Public Company

On February 15, 2011, Apio purchased 150,000 senior preferred shares for \$15 million and 201 common shares for \$201 that were issued by Windset Holdings 2010 Ltd., a Canadian corporation (“Windset”). On July 15, 2014, Apio increased its investment in Windset by purchasing an additional 68 common shares and 51,211 junior preferred shares of Windset for \$11 million. On October 29, 2014, Apio purchased an additional 70,000 senior preferred shares of Windset for \$7 million. These investments are reported as an investment in non-public company, fair value, in the accompanying Consolidated Balance Sheets as of February 26, 2017 and May 29, 2016. The Company has elected to account for its investment in Windset under the fair value option. See Note 2 – Investment in Non-public Company for further information.

Intangible Assets

The Company's intangible assets are comprised of customer relationships with a finite estimated useful life of twelve to thirteen years, and trademarks, tradenames and goodwill with indefinite lives.

Finite-lived intangible assets are reviewed for possible impairment whenever events or changes in circumstances occur that indicate that the carrying amount of an asset (or asset group) may not be recoverable. Indefinite lived intangible assets are reviewed for impairment at least annually. For goodwill and other indefinite-lived intangible assets, the Company performs a qualitative impairment analysis in accordance with Accounting Standards Codification (“ASC”) 350-30-35.

Fair Value Measurements

The Company uses fair value measurement accounting for financial assets and liabilities and for financial instruments and certain other items measured at fair value. The Company has elected the fair value option for its investment in a non-public company. See Note 2 – Investment in Non-public Company for further information. The Company has not elected the fair value option for any of its other eligible financial assets or liabilities.

The accounting guidance established a three-tier hierarchy for fair value measurements, which prioritizes the inputs used in measuring fair value as follows:

Level 1 – observable inputs such as quoted prices for identical instruments in active markets.

Level 2 – inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data.

Level 3 – unobservable inputs in which there is little or no market data, which would require the Company to develop its own assumptions.

As of February 26, 2017 and May 29, 2016, the Company held certain assets that are required to be measured at fair value on a recurring basis, including its interest rate swap and its minority interest investment in Windset.

The fair value of the Company’s interest rate swap is determined based on model inputs that can be observed in a liquid market, including yield curves, and is categorized as a Level 2 measurement and is recorded as other assets in the Consolidated Balance Sheet.

The Company has elected the fair value option of accounting for its investment in Windset. The calculation of fair value utilizes significant unobservable inputs, including projected cash flows, growth rates, and discount rates. As a result, the Company's investment in Windset is considered to be a Level 3 measurement investment. The change in the fair value of the Company's investment in Windset for the nine months ended February 26, 2017 was due to the Company's 26.9% minority interest in the change in the fair market value of Windset during the period. In determining the fair value of the investment in Windset, the Company utilizes the following significant unobservable inputs in the discounted cash flow models:

	February 26, 2017	May 29, 2016
Revenue growth rates	4%	4%
Expense growth rates	4%	4%
Income tax rates	15%	15%
Discount rates	12%	12.5%

The revenue growth, expense growth, and income tax rate assumptions are considered the Company's best estimate of the trends in those items over the discount period. The discount rate assumption takes into account the risk-free rate of return, the market equity risk premium, and the company's specific risk premium and then applies an additional discount for lack of liquidity of the underlying securities. The discounted cash flow valuation model used by the Company has the following sensitivity to changes in inputs and assumptions (in thousands):

	Impact on value of investment in Windset as of February 26, 2017
10% increase in revenue growth rates	\$ 7,200
10% increase in expense growth rates	\$ (2,100)
10% increase in income tax rates	\$ (400)
10% increase in discount rates	\$ (4,300)

Imprecision in estimating unobservable market inputs can affect the amount of gain or loss recorded for a particular position. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following table summarizes the fair value of the Company's assets and liabilities that are measured at fair value on a recurring basis (in thousands):

	Fair Value at February 26, 2017			Fair Value at May 29, 2016		
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3
Assets:						
Interest rate swap (1)	\$—	\$681	\$—	\$—	\$—	\$—
Investment in non-public company	—	—	63,400	—	—	62,700
Total	\$—	\$681	\$63,400	\$—	\$—	\$62,700

(1) Recorded in Other assets.

Revenue Recognition

See Note 11 – Business Segment Reporting, for a discussion about the Company's four business segments; namely, Packaged Fresh Vegetables, Food Export, Biomaterials, and Corporate.

Revenue from product sales is recognized when there is persuasive evidence that an arrangement exists, title has transferred, the price is fixed and determinable, and collectability is reasonably assured. Allowances are established for estimated uncollectible amounts, product returns, and discounts based on specific identification and historical losses.

Apio's Packaged Fresh Vegetables revenues generally consist of revenues generated from the sale of specialty packaged fresh-cut and whole value-added vegetable products that are generally washed and packaged in Apio's proprietary packaging and sold under Apio's Eat Smart and GreenLine brands and various private labels. Revenue is generally recognized upon shipment of these products to customers. The Company takes title to all produce it trades and/or packages, and therefore, records revenues and cost of sales at gross amounts in the Consolidated Statements of Comprehensive Income.

In addition, Packaged Fresh Vegetables revenues include the revenues generated from Apio Cooling, LP, a vegetable cooling operation in which Apio is the general partner with a 60% ownership position, and from the sale of BreatheWay® packaging to license partners. Revenue is recognized on the vegetable cooling operations as cooling and storage services are provided to Apio's customers. Sales of BreatheWay packaging are recognized when shipped to Apio's customers.

Apio's Food Export revenues consist of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products to Asia through its subsidiary, Cal-Ex Trading Company ("Cal-Ex"). As most Cal-Ex customers are in countries outside of the U.S., title transfers and revenue is generally recognized upon arrival of the shipment in the foreign port. Apio records revenue equal to the sale price to third parties because it takes title to the product while in transit.

Lifecore's Biomaterials business principally generates revenue through the sale of products containing HA. Lifecore primarily sells products to customers in three medical areas: (1) Ophthalmic, which represented approximately 55% of Lifecore's revenues in fiscal year 2016, (2) Orthopedic, which represented approximately 20% of Lifecore's revenues in fiscal year 2016, and (3) Other/Non-HA products, which represented approximately 25% of Lifecore's revenues in fiscal year 2016. The vast majority of Lifecore's revenues are recognized upon shipment.

Lifecore's business development revenues, a portion of which are included in all three medical areas, are related to contract research and development ("R&D") services and multiple element arrangement services with customers where the Company provides products and/or services in a bundled arrangement.

Contract R&D revenue is recorded as earned, based on the performance requirements of the contract. Non-refundable contract fees for which no further performance obligations exist, and there is no continuing involvement by the Company, are recognized on the earlier of when the payment is received or collection is assured.

For sales arrangements that contain multiple elements, the Company splits the arrangement into separate units of accounting if the individually delivered elements have value to the customer on a standalone basis. The Company also evaluates whether multiple transactions with the same customer or related party should be considered part of a multiple element arrangement, whereby the Company assesses, among other factors, whether the contracts or agreements are negotiated or executed within a short time frame of each other or if there are indicators that the contracts are negotiated in contemplation of each other. The Company then allocates revenue to each element based on a selling price hierarchy. The relative selling price for a deliverable is based on its vendor-specific objective evidence ("VSOE"), if available, third-party evidence ("TPE"), if VSOE is not available, or estimated selling price, if neither VSOE nor TPE is available. The Company then recognizes revenue on each deliverable in accordance with its policies for product and service revenue recognition. The Company is not typically able to determine VSOE or TPE, and therefore, uses the estimated selling price to allocate revenue between the elements of an arrangement.

The Company limits the amount of revenue recognition for delivered elements to the amount that is not contingent on the future delivery of products or services or future performance obligations or subject to customer-specific cancellation rights. The Company evaluates each deliverable in an arrangement to determine whether it represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has stand-alone value, and for an arrangement that includes a general right of return relative to the delivered products or services, delivery or performance of the undelivered product or service is considered probable and is substantially controlled by the Company. The Company considers a deliverable to have stand-alone value if the product or service is sold separately by the Company or another vendor or could be resold by the customer. Further, the revenue arrangements generally do not include a general right of return relative to delivered products. Where the aforementioned criteria for a separate unit of accounting are not met, the deliverable is combined with the undelivered element(s) and treated as a single unit of accounting for the purposes of allocation of the arrangement consideration and revenue recognition. The Company allocates the total arrangement consideration to each separable element of an arrangement based upon the relative selling price of each element. Allocation of the consideration is determined at arrangement inception on the basis of each unit's relative selling price. In instances where the Company has not established fair value for any undelivered element, revenue for all elements is deferred until delivery of the final element is completed and all recognition criteria are met.

For licensing revenue, the initial license fees are deferred and amortized to revenue over the period of the agreement when a contract exists, the fee is fixed and determinable, and collectability is reasonably assured. Noncancellable, nonrefundable license fees are recognized over the period of the agreement, including those governing research and development activities and any related supply agreement entered into concurrently with the license when the risk associated with commercialization of a product is non-substantive at the outset of the arrangement.

From time to time, the Company offers customers sales incentives, which include volume rebates and discounts. These amounts are estimated on a quarterly basis and recorded as a reduction of revenue.

A summary of revenues by type of arrangement as described above is as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	February 26,	February 28,	February 26,	February 28,
	2017	2016	2017	2016
Recorded upon shipment	\$125,765	\$118,789	\$339,917	\$341,914
Recorded upon acceptance in foreign port	7,276	6,389	56,316	50,873
Revenue from multiple element arrangements	2,624	4,025	5,892	9,672
Revenue from license fees, R&D contracts and royalties/profit sharing	903	787	2,702	3,327
Total	\$136,568	\$129,990	\$404,827	\$405,786

Legal Contingencies

In the ordinary course of business, the Company is involved in various legal proceedings and claims.

The Company makes a provision for a liability relating to legal matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These provisions are reviewed at least each fiscal quarter and adjusted to reflect the impacts of negotiations, estimated settlements, legal rulings, advice of legal counsel, and other information and events pertaining to a particular matter. Legal fees are expensed in the period in which they are incurred.

Apio has been the target of a union organizing campaign which has included two unsuccessful attempts to unionize Apio's Guadalupe, California processing plant. The campaign has involved a union and over 100 former and current employees of Pacific Harvest, Inc. and Rancho Harvest, Inc. (collectively "Pacific Harvest"), Apio's plant labor contractors, bringing legal actions before various state and federal agencies, the California Superior Court, and initiating over 100 individual arbitrations against Apio and Pacific Harvest.

The Company has been a co-defendant in civil actions and administrative actions involving claims filed by current and past employees of Pacific Harvest. The legal actions consist of three main types of claims: (1) Unfair Labor Practice claims ("ULPs") before the National Labor Relations Board ("NLRB"), (2) discrimination/wrongful termination claims before state and federal agencies and in individual arbitrations, and (3) wage and hour claims as part of two Private Attorney General Act ("PAGA") cases in state court and in over 100 individual arbitrations.

A settlement of the ULPs among a union, Apio, and Pacific Harvest that were pending before the NLRB was approved on December 27, 2016 for \$310,000. Apio was responsible for half of this settlement, or \$155,000. Concerning the discrimination/wrongful termination claims and the wage and hour claims, on February 23, 2017, the parties agreed in principle to a class action settlement which covers all non-exempt employees of Pacific Harvest working at Apio's Guadalupe, California processing facility. This settlement remains subject to all of the plaintiffs executing the settlement agreement, and the settlement agreement being approved by the Santa Barbara County Superior Court. Under the settlement agreement, the plaintiffs will be paid \$6.0 million in three installments: \$2.4 million in April 2017, \$1.8 million in November 2017, and \$1.8 million in July 2018. The Company and Pacific Harvest have each agreed to pay one half of the settlement.

Based on the initial number of asserted claims and the initial length of time covered by the claims, Apio had recorded a legal settlement contingency accrual of \$1.3 million as of November 27, 2016, which the Company believed at that time was sufficient to resolve its share of the costs of the legal actions prior to the broader settlement ultimately reached; which significantly increased the number of potential claims and the number of past years covered in the final settlement, thus resulting in the higher final settlement amount.

During the three and nine months ended February 26, 2017, the Company recorded a legal settlement charge of \$2.1 million and \$2.6 million, respectively, relating to these actions. As of February 26, 2017, the Company had accrued \$3.2 million relating to these actions, which is included in Other accrued liabilities in the accompanying Consolidated Balance Sheet.

Recently Adopted Accounting Guidance

Debt Extinguishment Costs

In August 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-15, *Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments* ("ASU 2016-15"). ASU 2016-15 clarifies how entities should classify certain cash receipts and cash payments in the statement of cash flows and amends certain disclosure requirements of ASC 230. ASU 2016-15 is intended to reduce diversity in practice with respect to eight types of cash flows including debt prepayment or debt extinguishment costs; proceeds from settlement of insurance claims; classification of cash receipts and payments that have aspects of more than one class of cash; and contingent consideration payments made after a business combination. The guidance is effective for fiscal years beginning after 15 December 2017, and interim periods within those years. Early adoption is permitted, including adoption in an interim period. The Company elected to early adopt ASU 2016-15 effective November 27, 2016. The adoption had no impact on our consolidated financial statements or related disclosures. The Company paid \$233,000 of early debt extinguishment penalties during the fiscal quarter ended November 27, 2016.

Debt Issuance Costs

In April 2015, the FASB issued ASU 2015-03, *Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs* (“ASU 2015-03”). The new guidance requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts, rather than as an asset, except in instances where proceeds from the related debt agreement have not been received.

In August 2015, the FASB issued ASU 2015-15, *Presentation and Subsequent Measurement of Debt Issuance Costs Associated With Line-of-Credit Arrangements* (“ASU 2015-15”). ASU 2015-15 amends Subtopic 835-30 to clarify that the Securities and Exchange Commission would not object to the deferral and presentation of debt issuance costs as an asset and subsequent amortization of the deferred costs ratably over the term of the line of credit arrangement, regardless of whether there are any outstanding borrowings on the arrangement.

The Company adopted ASU 2015-03 and ASU 2015-15 during its first fiscal quarter ended August 28, 2016 with retrospective application to its May 29, 2016 consolidated balance sheet. The effect of the adoption of ASU 2015-03 was to reclassify total debt issuance costs of \$817,000 as of May 29, 2016 as a deduction from the related debt liabilities. Accordingly, the May 29, 2016 consolidated balance sheet was adjusted as follows: (1) prepaid expenses and other current assets and total current assets were reduced by \$175,000 and current portion of long-term debt and total current liabilities were reduced by the same; (2) other assets were reduced by \$642,000 and long-term debt was reduced by the same; and (3) total assets were reduced by \$817,000 and total liabilities were reduced by the same. There was no effect related to the adoption of ASU 2015-15 given the Company has historically presented line of credit debt issuance costs as an asset, and as such, \$120,000 and \$431,000 remain as prepaid expenses and other current assets and other assets, respectively, as of February 26, 2017. ASU 2015-03 and ASU 2015-15 do not impact the income statement accounting for debt issuance costs; therefore, these costs will continue to be amortized to interest expense over the term of the related debt instruments. There was no effect on net income.

Stock-Based Compensation

In March 2016, the FASB issued ASU 2016-09, *Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting* (“ASU 2016-09”). The new guidance changes the accounting for certain aspects of stock-based payments to employees and requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. In addition, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. The standard also clarifies that all cash payments made on an employee’s behalf for withheld shares should be presented as a financing activity in the Company’s consolidated statements of cash flows and provides an accounting policy election to account for forfeitures as they occur. Finally, the new guidance eliminates the requirement to delay the recognition of excess tax benefits until it reduces current taxes payable. The new standard is effective for the Company beginning May 29, 2017, with early adoption permitted.

The Company elected to early adopt the new guidance in the quarter beginning May 30, 2016. Accordingly, the primary effects of the adoption are as follows: (1) using a modified retrospective application, the Company recorded unrecognized excess tax benefits of \$549,000 as a cumulative-effect adjustment, which increased retained earnings, and reduced deferred taxes by the same, (2) using a modified retrospective application, the Company has elected to recognize forfeitures as they occur and recorded a \$200,000 increase to additional paid-in capital, a \$126,000 reduction to retained earnings, and a \$74,000 reduction to deferred taxes to reflect the incremental stock-based compensation expense, net of the related tax impacts, that would have been recognized in prior years under the modified guidance, and (3) \$90,000 in excess tax benefits from stock-based compensation was reclassified from cash flows from financing activities to cash flows from operating activities for the nine months ended February 26, 2017 in the consolidated statements of cash flows. See Note 5 – Income Taxes for further information regarding additional effects related to the prospective application of excess tax benefits and tax deficiencies related to stock-based compensation on the Company’s financial statements.

Recent Accounting Guidance Not Yet Adopted

Leases

In February 2016, the FASB issued ASU 2016-02, *Leases (Topic 842)* (“ASU 2016-02”), which requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use-assets. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The new guidance is effective for the Company beginning in the first quarter of fiscal year 2020 on a modified retrospective basis, with early adoption permitted. Management is currently evaluating the effect ASU 2016-02 will have on the Company's Consolidated Financial Statements and disclosures.

Revenue Recognition

In May 2014, the FASB issued ASU 2014-09, which creates FASB ASC Topic 606, *Revenue from Contracts with Customers* and supersedes ASC Topic 605, *Revenue Recognition* (“ASU 2014-09”). The guidance replaces industry-specific guidance and establishes a single five-step model to identify and recognize revenue. The core principle of the guidance is that an entity should recognize revenue upon transfer of control of promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. Additionally, the guidance requires the entity to disclose further quantitative and qualitative information regarding the nature and amount of revenues arising from contracts with customers, as well as other information about the significant judgments and estimates used in recognizing revenues from contracts with customers. The effective date of ASU 2014-09 was deferred by the issuance of ASU 2015-14, *Revenue from Contracts with Customers: Deferral of the Effective Date, (Topic 606)* by one year to make the guidance of ASU 2014-09 effective for annual reporting periods beginning after December 15, 2017, including interim periods therein.

Early adoption is permitted, but not prior to the original effective date, which was for annual reporting periods beginning after December 15, 2016. In March 2016, the FASB issued ASU 2016-08, *Revenue from Contracts with Customers (Topic 606) Principal versus Agent Considerations (Reporting Revenue Gross versus Net)*, which clarifies how to apply the implementation guidance on principal versus agent considerations related to the sale of goods or services to a customer as updated by ASU 2014-09. In April 2016, the FASB issued ASU 2016-10, *Revenue from Contracts with Customers (Topic 606) Identifying Performance Obligations and Licensing*, which clarifies two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas, as updated by ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, *Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients*, which makes narrow scope amendments to Topic 606 including implementation issues on collectability, non-cash consideration and completed contracts at transition. The Company is currently assessing the future impact of this guidance on its consolidated financial statements and related disclosures and expects to adopt these updates beginning with the first quarter of its fiscal year 2019.

2. Investment in Non-public Company

On February 15, 2011, Apio entered into a share purchase agreement (the “Windset Purchase Agreement”) with Windset. Pursuant to the Windset Purchase Agreement, Apio purchased from Windset 150,000 Senior A preferred shares for \$15 million and 201 common shares for \$201. On July 15, 2014, Apio increased its investment in Windset by purchasing from the Newell Capital Corporation an additional 68 common shares and 51,211 junior preferred shares of Windset for \$11 million. After this purchase, the Company’s common shares represent a 26.9% ownership interest in Windset. The Senior A preferred shares yield a cash dividend of 7.5% annually. The dividend is payable within 90 days of each anniversary of the execution of the Windset Purchase Agreement. The non-voting junior preferred stock does not yield a dividend unless declared by the Board of Directors of Windset and no such dividend has been declared.

The Shareholders' Agreement between Apio and Windset includes a put and call option (the "Put and Call Option"), which can be exercised on or after the sixth anniversary of the Shareholders' Agreement whereby Apio can exercise the put to sell its common, Senior A preferred shares, and junior preferred shares to Windset, or Windset can exercise the call to purchase those shares from Apio, in either case, at a price equal to 26.9% of the fair market value of Windset's common shares, plus the liquidation value of the preferred shares of \$20.1 million (\$15 million for the Senior A preferred shares and \$5.1 million for the junior preferred shares). Under the terms of the arrangement with Windset, the Company is entitled to designate one of five members on the Board of Directors of Windset. On March 15, 2017, the Company and Windset amended the Shareholders' Agreement by extending the put/call date to March 31, 2022.

On October 29, 2014, Apio further increased its investment in Windset by purchasing 70,000 shares of Senior B preferred shares for \$7 million. The Senior B preferred shares pay an annual dividend of 7.5% on the amount outstanding at each anniversary date of the Windset Purchase Agreement. The Senior B preferred shares purchased by Apio have a put feature whereby Apio can sell back to Windset \$1.5 million of shares on the first anniversary, an additional \$2.75 million of shares on the second anniversary, and the remaining \$2.75 million on the third anniversary. After the third anniversary, Apio may at any time put any or all of the shares not previously sold back to Windset. At any time on or after February 15, 2017, Windset has the right to call any or all of the outstanding common shares, but at such time must also call the same proportion of Senior A preferred shares, Senior B preferred shares, and junior preferred shares owned by Apio. Windset's partial call provision is restricted such that a partial call cannot result in Apio holding less than 10% of Windset's common shares outstanding.

The investment in Windset does not qualify for equity method accounting as the investment does not meet the criteria of in-substance common stock due to returns through the annual dividend on the non-voting senior preferred shares that are not available to the common stock holders. As the put and call options require all of the various shares to be put or called in equal proportions, the Company has deemed that the investment, in substance, should be treated as a single security for purposes of accounting.

The fair value of the Company's investment in Windset was determined utilizing the Windset Purchase Agreement's put/call calculation for value and a discounted cash flow model based on projections developed by Windset, and considers the put and call conversion options. These features impact the duration of the cash flows utilized to derive the estimated fair values of the investment. These two discounted cash flow models' estimate for fair value are then weighted. Assumptions included in these discounted cash flow models will be evaluated quarterly based on Windset's actual and projected operating results to determine the change in fair value.

During each of the three months ended February 26, 2017 and February 28, 2016, the Company recorded \$412,500 in dividend income. During each of the nine months ended February 26, 2017 and February 28, 2016, the Company recorded \$1.2 million in dividend income. The increase in the fair market value of the Company's investment in Windset for the three months ended February 26, 2017 and February 28, 2016 was \$700,000 and \$0, respectively, and is included in other income in the Consolidated Statements of Comprehensive Income. The increase in the fair market value of the Company's investment in Windset for the nine months ended February 26, 2017 and February 28, 2016

was \$700,000 and \$1.0 million, respectively, and is included in other income in the Consolidated Statements of Comprehensive Income.

3. Stock-Based Compensation

The Company's stock-based awards include stock option grants and RSUs. The Company records compensation expense for stock-based awards issued to employees and directors in exchange for services provided based on the estimated fair value of the awards on their grant dates and is recognized over the required service periods, generally the vesting period.

The following table summarizes the stock-based compensation for options and RSUs (in thousands):

	Three Months Ended February 26, 28,		Nine Months Ended February 26, 28,	
	2017	2016	2017	2016
Options	\$ 308	\$ 331	\$ 907	\$ 1,021
RSUs	761	553	1,935	1,560
Total stock-based compensation	\$ 1,069	\$ 884	\$ 2,842	\$ 2,581

The following table summarizes the stock-based compensation by income statement line item (in thousands):

	Three Months Ended February 26, 2017		Nine Months Ended February 26, 2017	
	2016	2017	2016	2017
Cost of sales	\$ 103	\$ 124	\$ 301	\$ 361
Research and development	22	23	67	69
Selling, general and administrative	759	922	2,213	2,412
Total stock-based compensation	\$ 884	\$ 1,069	\$ 2,581	\$ 2,842

The estimated fair value for stock options, which determines the Company's calculation of stock-based compensation expense, is based on the Black-Scholes option pricing model. RSUs are valued at the closing market price of the Company's common stock on the date of grant. The Company uses the straight-line single option method to calculate and recognize the fair value of stock-based compensation arrangements.

As of February 26, 2017, there was \$5.8 million of total unrecognized compensation expense related to unvested equity compensation awards granted under the Landec incentive stock plans. Total expense is expected to be recognized over the weighted-average period of 1.7 years for stock options and 1.6 years for restricted stock unit awards.

4. Diluted Net Income Per Share

The following table sets forth the computation of diluted net income per share (in thousands, except per share amounts):

	Three Months Ended February 26, 2017		Nine Months Ended February 26, 2017	
	2016	2017	2016	2017
Numerator:				
Net income (loss) applicable to Common Stockholders	\$ (21,190)	\$ 3,500	\$ (16,370)	\$ 8,138
Denominator:				

Edgar Filing: LANDEC CORP \CA\ - Form 10-Q

Weighted average shares for basic net income per share	27,286	27,054	27,252	27,026
Effect of dilutive securities:				
Stock options and restricted stock units	396	—	356	—
Weighted average shares for diluted net income per share	27,682	27,054	27,608	27,026
Diluted net income (loss) per share	\$0.13	\$(0.78)	\$0.29	\$(0.61)

For the three and nine months ended February 26, 2017 the computation of the diluted net income per share excludes the impact of options to purchase 1.2 million and 1.4 million shares, respectively, of Common Stock as such impacts would be antidilutive for these periods.

Due to the Company's net loss for the three and nine months ended February 28, 2016, the net loss per share includes only weighted average shares outstanding and thus excludes 1.6 million and 1.5 million, respectively, of outstanding options and RSUs as such impacts would be antidilutive for these periods.

5. Income Taxes

The provision for income taxes for the three and nine months ended February 26, 2017 was \$1.6 million and \$4.1 million, respectively. The effective tax rate for the three and nine months ended February 26, 2017 was 31% and 34%, respectively. The effective tax rate for the three and nine months ended February 26, 2017 was lower than the statutory federal income tax rate of 35% primarily due to the domestic manufacturing deduction and research and development credits; partially offset by state taxes and non-deductible stock-based compensation expense.

The income tax benefit for the three and nine months ended February 28, 2016 was \$12.5 million and \$9.8 million, respectively. The effective tax rate for the three and nine months ended February 28, 2016 was 34% and 37%, respectively. The effective tax rate for the first nine months of fiscal year 2016 was higher than the statutory federal income tax rate of 35% primarily due to state taxes and non-deductible stock-based compensation expense; partially offset by the domestic manufacturing deduction and research and development credits. Included in the effective tax rate for the nine months ended February 28, 2016 is a \$12.5 million discrete tax benefit for the impairment of the GreenLine tradename.

As of February 26, 2017 and May 29, 2016, the Company had unrecognized tax benefits of approximately \$918,000 and \$842,000, respectively. Included in the balance of unrecognized tax benefits as of February 26, 2017 and May 29, 2016 is approximately \$778,000 and \$715,000, respectively, of tax benefits that, if recognized, would result in an adjustment to the Company's effective tax rate. In the twelve months following February 26, 2017, it is reasonably possible that approximately \$300,000 of other unrecognized tax benefits may be recognized.

During the nine months ended February 26, 2017, excess tax benefits related to stock-based compensation of \$80,000 were reflected in the consolidated statements of comprehensive income as a component of income tax expense as a result of the early adoption of ASU 2016-09, specifically related to the prospective application of excess tax benefits and tax deficiencies related to stock-based compensation. See Note 1— Organization, Basis of Presentation, and Summary of Significant Accounting Policies for further discussion regarding the adoption of ASU 2016-09.

The Company has elected to classify interest and penalties related to uncertain tax positions as a component of its provision for income taxes. The Company has accrued an insignificant amount of interest and penalties relating to the income tax on the unrecognized tax benefits as of February 26, 2017 and May 29, 2016.

Due to tax attribute carryforwards, the Company is subject to examination for tax years 1997 forward for U.S. tax purposes. The Company is also subject to examination in various state jurisdictions for tax years 1998 forward, none of which were individually material.

6. Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value and consists of the following (in thousands):

	February 26, 2017	May 29, 2016
Finished goods	\$ 10,105	\$ 12,165
Raw materials	10,188	9,855
Work in progress	2,980	3,515
Total	\$ 23,273	\$ 25,535

7. Debt

Long-term debt, net consists of the following (in thousands):

	February 26, 2017	May 29, 2016
Term loan with JPMorgan Chase Bank (“JPMorgan”), BMO Harris Bank N.A. (“BMO”), and City National Bank; due in quarterly principal and interest payments of \$1,250 beginning December 1, 2016 through September 23, 2021 with the remainder due on maturity, with interest based on the Company’s leverage ratio at a per annum rate of the Eurodollar rate plus a spread of between 1.25% and 2.25%	\$ 48,750	\$—
Real property loan agreement with General Electric Capital Corporation (“GE Capital”); due in monthly principal and interest payments of \$133 through May 1, 2022 with interest based on a fixed rate of 4.02% per annum	—	14,167
Capital equipment loan with GE Capital; due in monthly principal and interest payments of \$175 through May 1, 2019 with interest based on a fixed rate of 4.39% per annum	—	5,904
Capital equipment loan with GE Capital; due in monthly principal and interest payments of \$95 through July 17, 2019 with interest based on a fixed rate of 3.68% per annum	—	5,558
Capital equipment loan with GE Capital; due in monthly principal and interest payments of \$56 through December 1, 2019 with interest based on a fixed rate of 3.74% per annum	—	3,375
Capital equipment loan with Bank of America (“BofA”); due in monthly principal and interest payments of \$68 through June 28, 2020 with interest based on a fixed rate of 2.79% per annum	—	3,158
Real property loan agreement with GE Capital; due in monthly principal payments of \$32 through March 1, 2026, plus interest payable monthly at LIBOR plus 2.25% per annum	—	7,622
Capital equipment loan with GE Capital; due in monthly principal payments of \$108 through March 1, 2021, plus interest payable monthly at LIBOR plus 2.25% per annum	—	8,873
Capital equipment loan with BofA; due in monthly principal and interest payments of \$75 through November 27, 2020 with interest based on a fixed rate of 2.92% per annum	—	3,940
Industrial revenue bonds (“IRBs”) issued by Lifecore; due in annual payments through 2020 with interest at a variable rate set weekly by the bond remarketing agent (0.59% at May 29, 2016)	—	2,065
Total principal amount of long-term debt	48,750	54,662
Less: unamortized debt issuance costs	(276)	(817)
Total long-term debt, net of unamortized debt issuance costs	48,474	53,845
Less: current portion of long-term debt, net	(4,940)	(7,873)
Long-term debt, net	\$ 43,534	\$ 45,972

On September 23, 2016, the Company entered into a Credit Agreement with JPMorgan, BMO, and City National Bank, as lenders (collectively, the “Lenders”), and JPMorgan as administrative agent, pursuant to which the Lenders provided the Company with a \$100 million revolving line of credit (the “Revolver”) and a \$50 million term loan facility (the “Term Loan”), guaranteed by each of the Company’s direct and indirect subsidiaries and secured by substantially all of the Company’s assets, with the exception of the Company’s investment in Windset.

Both the Revolver and the Term Loan mature in five years (on September 23, 2021), with the Term Loan providing for quarterly principal payments of \$1.25 million commencing December 1, 2016, with the remainder due at maturity.

Interest on both the Revolver and the Term Loan is based on either the prime rate or Eurodollar rate, at the Company's discretion, plus a spread based on the Company's leverage ratio (generally defined as the ratio of the Company's total indebtedness on such date to the Company's consolidated earnings before interest, taxes, depreciation, and amortization ("EBITDA") for the period of four consecutive fiscal quarters ended on or most recently prior to such date). The spread is at a per annum rate of (i) between 0.25% and 1.25% if the prime rate is elected or (ii) between 1.25% and 2.25% if the Eurodollar rate is elected.

The Credit Agreement provides the Company the right to increase the Revolver commitments and/or the Term Loan commitments by obtaining additional commitments either from one or more of the Lenders or another lending institution at an amount of up to \$75 million.

The Credit Agreement contains customary financial covenants and events of default under which the obligation could be accelerated and/or the interest rate increased. The Company was in compliance with all financial covenants as of February 26, 2017.

On November 1, 2016, the Company entered into an interest rate swap agreement (“Swap”) with BMO at a notional amount of \$50 million. The Swap has the effect of changing the Company’s Term Loan obligation from a variable interest rate to a fixed 30-day LIBOR rate of 1.22%. As of February 26, 2017, the interest rate on the Term Loan was 2.97%. For further discussion regarding the Company’s use of derivative instruments, see the Financial Instruments section of Note 1 – Organization, Basis of Presentation, and Summary of Significant Accounting Policies.

In connection with the Credit Agreement, the Company incurred lender and third-party debt issuance costs of \$897,000, of which \$598,000 and \$299,000 was allocated to the Revolver and Term Loan, respectively.

As of February 26, 2017, no balance was outstanding on the Revolver.

Concurrent with the close of the Credit Agreement, all of the proceeds of the Term Loan, and \$1.5 million of the Revolver, was used by the Company to repay all then existing debt. Accordingly, the Company recognized a loss on debt refinancing of \$1.2 million, including \$233,000 of payments for early debt extinguishment penalties, for the quarter ended November 27, 2016, primarily related to the write-off of unamortized debt issuance costs on the Company’s then existing debt as of September 23, 2016.

8.Related Party

The Company sells products to and earns license fees from Windset. During the three months ended February 26, 2017 and February 28, 2016, the Company recognized revenues of \$72,000 and \$109,000, respectively. During the nine months ended February 26, 2017 and February 28, 2016, the Company recognized revenues of \$265,000 and \$376,000, respectively. These amounts have been included in product sales in the accompanying Consolidated Statements of Comprehensive Income. The associated receivable balances of \$150,000 and \$523,000 are included in accounts receivable in the accompanying Consolidated Balance Sheets as of February 26, 2017 and May 29, 2016, respectively.

All related party transactions are monitored quarterly by the Company and approved by the Audit Committee of the Board of Directors.

9. Stockholders' Equity

During the three months ended February 26, 2017, the Company granted options to purchase 60,000 shares of common stock and awarded 20,000 RSUs. During the nine months ended February 26, 2017, the Company granted options to purchase 240,000 shares of common stock and awarded 130,522 RSUs.

As of February 26, 2017, the Company has reserved 2.5 million shares of Common Stock for future issuance under its current and former equity plans.

On July 14, 2010, the Company announced that the Board of Directors of the Company had approved the establishment of a stock repurchase plan authorizing the repurchase of up to \$10 million of the Company's common stock. The Company may repurchase its common stock from time to time in open market purchases or in privately negotiated transactions. The timing and actual number of shares repurchased is at the discretion of management of the Company and will depend on a variety of factors, including stock price, corporate and regulatory requirements, market conditions, the relative attractiveness of other capital deployment opportunities and other corporate priorities. The stock repurchase program does not obligate Landec to acquire any amount of its common stock and the program may be modified, suspended or terminated at any time at the Company's discretion without prior notice. During the fiscal year ended May 29, 2016 and the three and nine months ended February 26, 2017, the Company did not purchase any shares on the open market.

10. Comprehensive Income

Comprehensive income consists of two components, net income and Other Comprehensive Income ("OCI"). OCI refers to revenue, expenses, and gains and losses that under GAAP are recorded as a component of stockholders' equity but are excluded from net income. The Company's OCI consists of net deferred gains and losses on its interest rate swap derivative instrument accounted for a cash flow hedge. The components of OCI, net of tax, are as follows (in thousands):

	Unrealized Gains on
	Cash Flow Hedge
Balance as of May 29, 2016	\$ —
Other comprehensive income before reclassifications, net of tax effect	430
Amounts reclassified from OCI	(—)
Other comprehensive income, net	430
Balance as of February 26, 2017	\$ 430

The Company does not expect any transactions or other events to occur that would result in the reclassification of any significant gains into earnings in the next 12 months.

11. Business Segment Reporting

The Company manages its business operations through three strategic business units. Based upon the information reported to the chief operating decision maker, who is the Chief Executive Officer, the Company has the following reportable segments: the Packaged Fresh Vegetables segment, the Food Export segment, and the Biomaterials segment.

The Packaged Fresh Vegetables segment markets and packs specialty packaged whole and fresh-cut vegetables, the majority of which incorporate the BreatheWay specialty packaging for the retail grocery, club store, and food services industries. In addition, the Packaged Fresh Vegetables segment sells BreatheWay packaging to partners for fruit and vegetable products. The Food Export segment consists of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products primarily to Asia. The Biomaterials segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic, and other markets. Corporate licenses Landec's Intelimer polymers for agricultural products, personal care products, and other industrial products. The Corporate segment also includes general and administrative expenses, non-Packaged Fresh Vegetables and non-Biomaterials interest income and income tax expenses. All of the assets of the Company are located within the United States of America. The Company's international sales were as follows (in millions):

	Three Months Ended February		Nine Months Ended February	
	26,	28,	26,	28,
	2017	2016	2017	2016
Canada	\$16.6	\$20.3	\$50.6	\$60.6
Taiwan	\$3.0	\$1.2	\$27.9	\$26.6
Belgium	\$12.9	\$6.2	\$19.8	\$7.3
China	\$0.4	\$0.3	\$11.8	\$7.6
Indonesia	\$1.5	\$2.4	\$6.6	\$6.3
Japan	\$1.3	\$1.0	\$6.2	\$4.6
Philippines	\$0.6	\$0.5	\$1.9	\$2.1
All Other Countries	\$2.8	\$3.4	\$8.5	\$10.5

Operations by business segment consisted of the following (in thousands):

Three Months Ended February 26, 2017	Packaged Fresh	Food Export	Biomaterials	Corporate	Total
	Vegetables				
Net sales	\$ 105,447	\$ 7,276	\$ 23,532	\$ 313	\$ 136,568
International sales	\$ 16,802	\$ 7,276	\$ 15,024	\$ —	\$ 39,102
Gross profit	\$ 10,114	\$ 558	\$ 12,581	\$ 179	\$ 23,432
Net income (loss)	\$ (2,492)	\$ (116)	\$ 7,135	\$ (1,027)	\$ 3,500
Depreciation and amortization	\$ 1,862	\$ —	\$ 794	\$ 61	\$ 2,717
Dividend income	\$ 413	\$ —	\$ —	\$ —	\$ 413
Interest income	\$ 8	\$ —	\$ —	\$ —	\$ 8
Interest expense, net	\$ (77)	\$ —	\$ —	\$ 477	\$ 400
Income tax expense (benefit)	\$ (594)	\$ (33)	\$ 2,031	\$ 152	\$ 1,556
Three Months Ended February 28, 2016					
Net sales	\$ 107,348	\$ 6,389	\$ 15,701	\$ 552	\$ 129,990
International sales	\$ 20,343	\$ 6,389	\$ 8,576	\$ —	\$ 35,308
Gross profit	\$ 4,334	\$ 521	\$ 7,618	\$ 458	\$ 12,931
Net income (loss)	\$ (36,963)	\$ (27)	\$ 3,450	\$ 12,350	\$ (21,190)
Depreciation and amortization	\$ 1,455	\$ —	\$ 656	\$ 36	\$ 2,147
Dividend income	\$ 413	\$ —	\$ —	\$ —	\$ 413
Interest income	\$ 17	\$ —	\$ —	\$ —	\$ 17
Interest expense, net	\$ 427	\$ —	\$ 57	\$ —	\$ 484
Income tax expense (benefit)	\$ (905)	\$ (189)	\$ 973	\$ (12,389)	\$ (12,510)
Nine Months Ended February 26, 2017					
Net sales	\$ 299,370	\$ 56,316	\$ 47,795	\$ 1,346	\$ 404,827
International sales	\$ 51,073	\$ 56,316	\$ 25,896	\$ —	\$ 133,285
Gross profit	\$ 36,522	\$ 3,436	\$ 22,640	\$ 931	\$ 63,529
Net income (loss)	\$ (419)	\$ 812	\$ 9,690	\$ (1,945)	\$ 8,138
Depreciation and amortization	\$ 5,474	\$ 3	\$ 2,225	\$ 125	\$ 7,827
Dividend income	\$ 1,238	\$ —	\$ —	\$ —	\$ 1,238
Interest income	\$ 15	\$ —	\$ —	\$ —	\$ 15
Interest expense, net	\$ 594	\$ —	\$ 13	\$ 825	\$ 1,432
Income tax expense (benefit)	\$ (81)	\$ 229	\$ 2,769	\$ 1,221	\$ 4,138
Nine Months Ended February 28, 2016					
Net sales	\$ 318,218	\$ 50,873	\$ 34,748	\$ 1,947	\$ 405,786
International sales	\$ 60,948	\$ 50,873	\$ 13,735	\$ —	\$ 125,556
Gross profit	\$ 27,565	\$ 3,200	\$ 15,713	\$ 1,695	\$ 48,173
Net income (loss)	\$ (34,361)	\$ 1,250	\$ 4,911	\$ 11,830	\$ (16,370)
Depreciation and amortization	\$ 4,470	\$ 1	\$ 1,902	\$ 113	\$ 6,486
Dividend income	\$ 1,238	\$ —	\$ —	\$ —	\$ 1,238
Interest income	\$ 39	\$ —	\$ 25	\$ —	\$ 64

Interest expense, net	\$ 1,304	\$—	\$ 121	\$—	\$1,425
Income tax expense (benefit)	\$—	\$—	\$ 1,385	\$(11,135)	\$(9,750)

During the nine months ended February 26, 2017 and February 28, 2016, sales to the Company's top five customers accounted for 43% and 45%, respectively, of sales. The Company's top two customers, Costco Wholesale Corporation and Wal-Mart Stores, Inc., from the Packaged Fresh Vegetables segment accounted for 17% and 14% of revenues, respectively, for the nine months ended February 26, 2017, and 20% and 12% respectively, for the nine months ended February 28, 2016. The Company expects that, for the foreseeable future, a limited number of customers may continue to account for a significant portion of its net sales.

12. Subsequent Events

On March 1, 2017, the Company purchased substantially all of the assets of O Olive Oil, Inc. (“O Olive”) for \$2.5 million in cash plus contingent consideration of up to \$7.5 million over the next three years based upon O Olive achieving certain EBITDA targets. O Olive, founded in 1995, is based in Petaluma, California, and is the premier producer of California specialty olive oils and wine vinegars. Its products are sold in natural food, conventional grocery and mass retail stores, primarily in the United States and Canada.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the unaudited consolidated financial statements and accompanying notes included in Part I, Item 1, of this Form 10-Q and the audited consolidated financial statements and accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Landec’s Annual Report on Form 10-K for the fiscal year ended May 29, 2016.

Except for the historical information contained herein, the matters discussed in this report are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Potential risks and uncertainties include, without limitation, those mentioned in this Form 10-Q and those mentioned in Landec’s Annual Report on Form 10-K for the fiscal year ended May 29, 2016. Landec undertakes no obligation to update or revise any forward-looking statements in order to reflect events or circumstances that may arise after the date of this report.

Critical Accounting Policies and Use of Estimates

There have been no material changes to the Company's critical accounting policies which are included and described in the Form 10-K for the fiscal year ended May 29, 2016 filed with the Securities and Exchange Commission on July 29, 2016.

See Note 1 – Organization, Basis of Presentation, and Summary of Significant Accounting Policies of the Notes to Consolidated Financial Statements for a discussion of recently adopted accounting guidance and recent accounting guidance not yet adopted.

Derivative Instruments and Hedging

The Company entered into an interest rate swap agreement to manage interest rate risk, and designated this derivative instrument as a cash flow hedge. See Note 1 – Organization, Basis of Presentation, and Summary of Significant Accounting Policies and Note 10 – Comprehensive Income of the Notes to Consolidated Financial Statements for further discussion.

The Company

Landec Corporation and its subsidiaries (“Landec” or the “Company”) design, develop, manufacture, and sell differentiated health and wellness products for food and biomaterials markets. There continues to be a dramatic shift in consumer behavior to healthier eating habits and preventive wellness to improve quality of life. The Apio, Inc. (“Apio”) Packaged Fresh Vegetables business is committed to offering healthy, fresh produce products conveniently packaged to consumers. Apio also exports whole fruit and vegetables, predominantly to Asia through its subsidiary, Cal-Ex Trading Company (“Cal-Ex”). In the Lifecore Biomedical, Inc. (“Lifecore”) biomaterials business, we commercialize products that enable people to stay more active as they grow older.

Landec’s Packaged Fresh Vegetables and Biomaterials businesses utilize polymer chemistry technology, a key differentiating factor. Both businesses focus on business-to-business selling such as selling directly to retail grocery store chains and club stores for Apio, and directly to partners in the medical device and pharmaceutical markets, with a concentration in ophthalmology for Lifecore.

Within Landec’s two core businesses, there are three operating segments – Packaged Fresh Vegetables, Food Export, and Biomaterials, each of which is described below.

Apio operates the Packaged Fresh Vegetables business, which combines proprietary BreatheWay® food packaging technology with the capabilities of a large national food supplier and value-added produce processor which sells products under the Eat Smart brand to consumers and the GreenLine® brand to foodservice operators, as well as under private labels. In Apio’s Packaged Fresh Vegetables operations, produce is processed by trimming, washing, sorting, blending, and packaging into bags and trays that generally incorporates Landec’s BreatheWay membrane technology. The BreatheWay membrane increases shelf-life and reduces shrink (waste) for retailers and helps to ensure that consumers receive fresh produce by the time the product makes its way through the supply chain. Apio also generates revenue from the sale and/or use of its BreatheWay technology by partners such as Chiquita Brands International, Inc. (“Chiquita”) for packaging and distribution of bananas and berries and Windset Holdings 2010 Ltd., a Canadian corporation (“Windset”), for packaging of greenhouse grown cucumbers and peppers, and to Juicero, Inc. (“Juicero”) innovator of the first in-home cold-press fruit and vegetable juicing system. Juicero is using BreatheWay membranes to extend the shelf-life of fresh fruit and vegetables packets.

Apio also operates the Food Export business. The Food Export business purchases and sells whole fruit and vegetable commodities predominantly to Asian markets.

Lifecore operates the Biomaterials business and is principally involved in the development and manufacture of pharmaceutical-grade sodium hyaluronate (“HA”) products and aseptic contract manufacturing. Sodium hyaluronate is a naturally occurring polysaccharide that is widely distributed in the extracellular matrix in animals and humans. Based upon Lifecore’s expertise working with highly viscous HA, the Company specializes in fermentation and aseptic filling services, as a contract development and manufacturing organization, for difficult to handle (viscous) medicines filled in finished dose syringes.

Landec was incorporated on October 31, 1986. The Company completed its initial public offering in 1996 and its Common Stock is listed on the NASDAQ Global Select Market under the symbol “LNDC.” The Company’s principal executive offices are located at 3603 Haven Avenue, Menlo Park, California 94025, and the telephone number is (650) 306-1650.

Description of Core Business

Landec operates its business in three core business segments: Packaged Fresh Vegetables, Food Export and Biomaterials.

Packaged Fresh Vegetables Business

Based in Guadalupe, California, Apio’s primary business is fresh-cut and whole vegetable products primarily packaged in proprietary BreatheWay packaging. The Packaged Fresh Vegetables business markets a variety of fresh-cut and whole vegetables to the top retail grocery chains, club stores, and food service operators. During the fiscal year ended May 29, 2016, Apio shipped approximately 30 million cartons of produce to its customers throughout North America, primarily in the United States.

There are four major distinguishing characteristics of Apio that provide competitive advantages in the Packaged Fresh Vegetables market:

Packaged Vegetables Supplier: Apio has structured its business as a marketer and seller of branded and private label blended, fresh-cut, and whole vegetable products. It is focused on selling products primarily under its Eat
(1) Smart brand, with some sales under its GreenLine brand, and private label brands. As retail grocery chains, club stores, and food service operators consolidate, Apio is well positioned as a single source of a broad range of products.

Nationwide Processing and Distribution: Apio has strategically invested in its Packaged Fresh Vegetables business. Apio's largest processing plant is in Guadalupe, CA, and is automated with state-of-the-art vegetable
(2) processing equipment in one of the lowest cost, growing regions in California, the Santa Maria Valley. With the acquisition of GreenLine in 2012, Apio added three East Coast processing facilities and five East Coast distribution facilities for nationwide delivery of all of its packaged vegetable products in order to meet the next-day delivery needs of customers.

Expanded Product Line Using Technology and Unique Blends: Apio, through the use of its BreatheWay
(3) packaging technology, is introducing new packaged vegetable products each year. These new product offerings range from various sizes of vegetable salads, fresh-cut bagged products, vegetable trays, whole produce, and snack packs. During the last twelve months, Apio has introduced six new unique products.

- (4) **Products Currently in Approximately 60% of U.S. Retail Grocery Stores:** Apio has products in approximately 60% of all U.S. retail grocery stores. This gives Apio the opportunity to sell new products to existing customers and to increase distribution of its approximately 120 unique products within those customers.

Most vegetable products packaged in Apio's BreatheWay packaging have an approximate 17 day shelf-life. In addition to packaging innovation, Apio has developed innovative blends and combinations of vegetables that are sold in flexible film bags or rigid trays. More recently, Apio has launched a family of salad kits that are comprised of "superfood" mixtures of vegetables with healthy toppings and dressings. The first salad kit to launch under the Eat Smart® brand was Sweet Kale Salad, which now has significant distribution throughout club and retail stores in North America. Additionally, we have launched under the Eat Smart brand several other superfood salad kits including Ginger Bok Choy, Wild Greens and Quinoa, Beets and Greens, Southwest Salad, and Asian Sesame. The Company's expertise includes accessing leading culinary experts and nutritionists nationally to help in the new product development process. We believe that the Company's new products are "on trend" and strong market acceptance supports this belief. Recent statistics show that more than two-thirds of adults are considered to be overweight or obese and more than one-third of adults are considered to be obese. More and more consumers are beginning to make better food choices in their schools, homes, and in restaurants and that is where the superfood products can fit into consumers' daily healthy food choices.

In addition to proprietary packaging technology and a strong new product development pipeline, the Company has strong channels of distribution throughout North America with retail grocery store chains and club stores. Landec has one or more of its products in approximately 60% of all retail and club store sites in the U.S. giving it a strong platform for introducing new products.

The Company sells its products under its nationally-known brand Eat Smart to retail and club stores and its GreenLine brand to foodservice operators. The Company also periodically licenses its BreatheWay packaging technology to partners such as Chiquita for packaging bananas and berries, and Windset for packaging peppers and cucumbers that are grown hydroponically in greenhouses. The Company also licenses its BreatheWay technology to Juicero to extend the shelf-life of fresh produce packets for use in a countertop juicing system. These packaging license relationships generate revenues either from product sales or royalties once commercialized. The Company is engaged in the testing and development of other BreatheWay products. Landec manufactures its BreatheWay packaging through selected qualified contract manufacturers.

Windset

The Company believes that hydroponically-grown produce using Windset's know-how and growing practices will result in higher yields with competitive growing costs that will provide dependable year-round supply to Windset's customers. In addition, the produce grown in Windset's greenhouses uses significantly less water than field grown crops and has a very high safety profile as no soil is used in the growing process. Windset owns and operates

greenhouses in British Columbia, Canada and in Nevada and California. In addition to growing produce in its own greenhouses, Windset has numerous marketing arrangements with other greenhouse growers and utilizes buy/sell arrangements to meet fluctuation in demand from their customers.

On March 15, 2017, the Company and Windset agreed to extend their relationship at least through March 31, 2022.

See Note 2 – Investment in Non-public Company of the Notes to Consolidated Financial Statements for a discussion about the Company’s 26.9% minority ownership interest in Windset.

Food Export Business

Food Export revenues consist of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products primarily to Asia through Apio’s export company, Cal-Ex. The Food Export business is a buy/sell business that realizes a margin on average in the 5-10% range.

Biomaterials Business

Lifecore uses its fermentation process and aseptic formulation and filling expertise to be a leader in the development of HA-based products for multiple applications and to take advantage of non-HA device and drug opportunities which leverage its expertise in manufacturing and aseptic syringe filling capabilities. Elements of Lifecore’s strategy include the following:

Establish strategic relationships with market leaders: Lifecore will continue to develop applications for products with partners who have strong marketing, sales, and distribution capabilities to end-user markets.

- (1) Through its strong reputation and history of providing pharmaceutical grade HA and products, Lifecore has been able to establish long-term relationships with the market leading ophthalmic surgical companies, and leverages those partnerships to attract new relationships in other medical markets.

- Expand medical applications for HA:** Due to the growing knowledge of the unique characteristics of HA, and the role it plays in normal physiology, Lifecore continues to identify opportunities for the use of HA in other medical applications, such as wound care, aesthetic surgery, drug delivery, device coatings, and through pharmaceutical sales to academic and corporate research customers.

- Utilize manufacturing infrastructure to pursue contract aseptic filling and fermentation opportunities:** Lifecore has made strategic capital investments in its contract manufacturing and development business focusing on extending its aseptic filling capacity and capabilities. It is investing in this segment to meet increasing partner demand and attract new contract filling opportunities. Lifecore is using its manufacturing capabilities to provide contract manufacturing and development services to its partners in the area of sterile pre-filled syringes and fermentation and purification requirements.

- Maintain flexibility in product development and supply relationships:** Lifecore's vertically integrated development and manufacturing capabilities allow it to establish a variety of contractual relationships with global corporate partners. Lifecore's role in these relationships extends from supplying HA raw materials to providing tech transfer and development services to manufacturing aseptically-packaged, finished sterile products, and to assuming full supply chain responsibilities.

Results of Operations

Revenues (in thousands):

	Three Months Ended			Change	Nine Months Ended			Change
	February 26, 2017	February 28, 2016			February 26, 2017	February 28, 2016		
Packaged Fresh Vegetables	\$105,447	\$107,348	(2	%)	\$299,370	\$318,218	(6	%)
Food Export	7,276	6,389	14	%	56,316	50,873	11	%
Total Apio	112,723	113,737	(1	%)	355,686	369,091	(4	%)
Biomaterials	23,532	15,701	50	%	47,795	34,748	38	%
Corporate	313	552	(43	%)	1,346	1,947	(31	%)
Total Revenues	\$136,568	\$129,990	5	%	\$404,827	\$405,786	0	%

Packaged Fresh Vegetables (Apio)

Apio's Packaged Fresh Vegetables revenues consist of revenues generated from the sale of specialty packaged fresh-cut and whole processed vegetable products that are washed and packaged in Apio's proprietary packaging and sold under the Eat Smart and GreenLine brands and various private labels. In addition, the Packaged Fresh Vegetables revenues include the revenues generated from Apio Cooling, LP, a vegetable cooling operation in which Apio is the

general partner with a 60% ownership position and from the sale of BreatheWay packaging to license partners.

The decrease in Apio's Packaged Fresh Vegetables revenues for the three months ended February 26, 2017 compared to the same period last year was primarily due to loss of some club store business in retail grocery stores for salad kit products during the quarter and the loss of some low margin core packaged vegetable business which began in the second half of fiscal year 2016. These losses were partially offset by increased sales volume to food service customers.

The decrease in Apio's Packaged Fresh Vegetables revenues for the nine months ended February 26, 2017 compared to the same period last year was primarily due to a 5% decrease in unit volume sales primarily due to the loss of some low margin core packaged vegetable business in retail grocery stores which began in the second half of fiscal year 2016.

Food Export (Apio)

Apio's Food Export revenues consist of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products to Asia by Cal-Ex. Apio records revenue equal to the sale price to third parties because it takes title to the product while in transit.

The increase in Apio's Food Export revenues for the three months ended February 26, 2017 compared to the same period last year was due to a 13% increase in unit volume sales primarily due to procurement of additional fruit supplies.

The increase in Apio's Food Export revenues for the nine months ended February 26, 2017 compared to the same period last year was due to a 16% increase in unit volume sales and procurement of additional fruit supplies, partially offset by a shift in product mix during the first half of fiscal year 2017 to lower priced fruit commodity products.

Biomaterials (Lifecore)

Lifecore principally generates revenue through the sale of products containing HA. Lifecore primarily sells products to customers in three medical areas: (1) Ophthalmic, which represented approximately 55% of Lifecore's revenues in fiscal year 2016, (2) Orthopedic, which represented approximately 20% of Lifecore's revenues in fiscal year 2016, and (3) Other/Non-HA products, which represented approximately 25% of Lifecore's revenues in fiscal year 2016.

The increase in Lifecore's revenues for the three months ended February 26, 2017 compared to the same period last year was due to a \$6.5 million increase in fermentation sales resulting from higher sales to existing customers and a \$2.3 million increase in aseptic filling revenues due to new commercial aseptic business and an increase in sales to existing customers, partially offset by a \$1.0 million decrease in development revenues due to the approval of a customer's drug product that is now being commercially sold.

The increase in Lifecore's revenues for the nine months ended February 26, 2017 compared to the same period last year was due to a \$13.0 million increase in fermentation sales resulting from higher sales to existing customers and a \$3.8 million increase in aseptic filling revenues due to new commercial aseptic business and an increase in sales to existing customers, partially offset by a \$3.8 million decrease in development revenues primarily due to the approval of a customer's drug product that is now being commercially sold.

Corporate

Corporate revenues consist of revenues generated from licensing agreements with partners.

The decrease in Corporate revenues for the three and nine months ended February 26, 2017 compared to the same period last year was not significant.

Gross Profit (in thousands):

	Three Months Ended				Nine Months Ended			
	February 26,	February 28,	Change		February 26,	February 28,	Change	
	2017	2016			2017	2016		
<i>Packaged Fresh Vegetables</i>	\$10,114	\$4,334	133	%	\$36,522	\$27,565	32	%
<i>Food Export</i>	558	521	7	%	3,436	3,200	7	%
<i>Total Apio</i>	10,672	4,855	120	%	39,958	30,765	30	%
<i>Biomaterials</i>	12,581	7,618	65	%	22,640	15,713	44	%
<i>Corporate</i>	179	458	(61)	%)	931	1,695	(45)	%)
<i>Total Gross Profit</i>	\$23,432	\$12,931	81	%	\$63,529	\$48,173	32	%

General

There are numerous factors that can influence gross profit including, but not limited to: product mix, customer mix, manufacturing costs, volume, sale discounts, and charges for excess or obsolete inventory. Many of these factors influence or are interrelated with other factors. The Company includes in cost of sales all of the costs related to the sale of products in accordance with GAAP. These costs include the following: raw materials (including produce, packaging, syringes and fermentation and purification supplies), direct labor, overhead (including indirect labor, depreciation, and facility-related costs), and shipping and shipping-related costs. The following are the primary reasons for the changes in gross profit for the three and nine months ended February 26, 2017 compared to the same periods last year as outlined in the table above.

Packaged Fresh Vegetables (Apio)

The increase in gross profit for Apio's Packaged Fresh Vegetables business for the three and nine months ended February 26, 2017 compared to the same periods last year was primarily due to the gross profit generated from a favorable mix shift in revenues to a greater percentage of revenues coming from higher margin products due primarily to the loss of some low margin business which began in the second half of fiscal year 2016, operational productivity improvement initiatives, and from the fact that during the three and nine months ended February 28, 2016, Apio incurred approximately \$6.6 million and \$12.6 million, respectively, of excess costs from produce shortages. These factors resulted in gross margin increasing to 9.6% during the three months ended February 26, 2017 from 4.0% for the same period last year and increasing to 15.9% during the nine months February 26, 2017 from 8.7% for the same period last year.

Food Export (Apio)

Apio's Food Export business is a buy/sell business that realizes a commission-based margin typically in the 5-10% range. The increase in gross profit for Apio's Food Export business during the three and nine months ended February 26, 2017 compared to the same periods last year was primarily due to the 14% and 11% increase, respectively, in revenues. These higher revenues were driven by an abundant supply of export product resulting in lower margins for the volume sold and lower gross margins of 7.7% and 6.1% for the three and nine months ended February 26, 2017 compared to gross margin of 8.2% and 6.3% for the same periods last year.

Biomaterials (Lifecore)

The increase in Lifecore's gross profit for the three and nine months ended February 26, 2017 compared to the same periods last year was higher than the 50% and 38% increase, respectively, in revenues as a result of a favorable product mix change to a higher percentage of revenue coming from higher margin fermentation sales than from lower margin aseptically filled product sales during the same period last year.

Corporate

The decrease in Corporate gross profit for the three and nine months ended February 26, 2017 compared to the same period last year was not significant.

Operating Expenses (in thousands):

	Three Months Ended				Nine Months Ended			
	February 26,	February 28,	Change		February 26,	February 28,	Change	
	2017	2016			2017	2016		
Research and Development:								
<i>Apio</i>	\$339	\$272	25	%	\$862	\$731	18	%
<i>Lifecore</i>	1,362	1,217	12	%	4,027	3,529	14	%
<i>Corporate</i>	313	406	(23	%)	1,028	1,153	(11	%)
Total R&D	2,014	1,895	6	%	5,917	5,413	9	%
Selling, General and Administrative:								
<i>Apio</i>	10,447	7,021	49	%	29,296	23,866	23	%
<i>Lifecore</i>	1,362	1,271	7	%	4,072	3,841	6	%
<i>Corporate</i>	3,200	2,367	35	%	8,601	7,931	8	%
Total SG&A	\$15,009	\$10,659	41	%	\$41,969	\$35,638	17	%

Research and Development

Landec's Research and Development ("R&D") consisted primarily of product development and commercialization initiatives. R&D efforts at Apio are focused on the Company's proprietary BreatheWay membranes used for packaging produce, with a focus on extending the shelf-life of sensitive vegetables and fruit. In the Lifecore business, the R&D efforts are focused on new products and applications for HA-based and non-HA biomaterials. For Corporate, the R&D efforts are primarily focused on supporting the development and commercialization of new products and new technologies in the food and HA businesses, and on new R&D collaborations with partners.

The increase in R&D expenses for the three and nine months ended February 26, 2017 compared to the same periods last year was primarily due to an increase in development activity at Lifecore this year compared to last year.

Selling, General and Administrative

Selling, general and administrative (“SG&A”) expenses consist primarily of sales and marketing expenses associated with Landec’s product sales and services, business development expenses, and staff and administrative expenses.

The increase in SG&A expenses for the three and nine months ended February 26, 2017 compared to the same periods last year was primarily due to an increase in expenses at Apio primarily to ramp up product launches, advertising, and promotions of Apio’s existing and new salad kit products to drive current and future sales, additional headcount hired over the past year, and from an increase at Corporate primarily due to an increase in stock based compensation from equity grants during the last year and from new business development activities.

Other (in thousands):

	Three Months Ended February 26, 2017				Nine Months Ended February 26, 2017			
	2017	2016	Change		2017	2016	Change	
Dividend Income	\$413	\$413	0	%	\$1,238	\$1,238	0	%
Interest Income	8	17	(53	%)	15	64	(77	%)
Interest Expense, net	400	484	(17	%)	1,432	1,425	0	%
Loss on Debt Refinancing	—	—	0	%	(1,233)	—	N/M	
Other Income	700	—	N/M		700	1,000	(30	%)
Income Tax Expense (Benefit)	1,556	(12,510)	N/M		4,138	(9,750)	N/M	
Non-controlling Interest	6	(23)	(126	%)	(75)	(119)	(37	%)

Dividend Income

Dividend income is derived from the dividends accrued on the Company’s \$22 million senior preferred stock investment in Windset which yields a cash dividend of 7.5% annually. There was no change in dividend income for the three and nine months ended February 26, 2017 compared to the same periods last year.

Interest Income

The decrease in interest income for the three and nine months ended February 26, 2017 compared to the same periods last year was not significant.

Interest Expense

The change in interest expense for the three and nine months ended February 26, 2017 compared to the same periods last year was not significant.

Loss on Debt Refinancing

The loss on debt refinancing for the nine months ended February 26, 2017 was primarily due to the one-time write-off of unamortized debt issuance costs and early debt extinguishment prepayment penalties on the Company's then existing debt as of September 23, 2016.

Other Income

The change in other income for the three and nine months ended February 26, 2017 was a result of the change in the fair value of the Company's investment in Windset which increased \$700,000 for the three and nine months ended February 26, 2017.

Income Taxes

The increase in the income tax expense during the three and nine months ended February 26, 2017 compared to the same periods last year was due to the Company generating net income during the third quarter and first nine months of fiscal year 2017 compared to realizing a loss for those same periods last year.

Non-controlling Interest

The non-controlling interest consists of the limited partners' equity interest in the net income of Apio Cooling, LP. The decrease in the non-controlling interest for the three and nine months ended February 26, 2017 compared to the same periods last year was not significant.

Liquidity and Capital Resources

As of February 26, 2017, the Company had cash and cash equivalents of \$12.7 million, a net increase of \$2.8 million from \$9.9 million as of May 29, 2016.

Cash Flow from Operating Activities

Landec generated \$23.2 million of cash from operating activities during the nine months ended February 26, 2017, compared to generating \$6.4 million of cash from operating activities for the nine months ended February 28, 2016. The primary sources of cash from operating activities during the nine months ended February 26, 2017 were from (1) \$8.2 million of net income, (2) \$10.7 million of depreciation/amortization and stock based compensation expenses, and (3) a \$3.4 million net increase in deferred tax liabilities. These sources of cash were minimally offset by a net decrease of \$65,000 in working capital. The primary factors which decreased working capital during the first nine months of fiscal year 2017 were (1) a \$2.3 million decrease in inventories due to a \$2.0 million decrease at Lifecore as a result of the large volume of shipments during the third quarter of fiscal year 2017, and (2) a \$3.4 million increase in other accrued liabilities due primarily to increasing the legal settlement accrual by \$2.6 million during the first nine months of fiscal year 2017. The decreases in working capital were offset by a \$6.1 million decrease in accounts payable due to decreases of \$3.9 million at Apio and \$2.1 million at Lifecore resulting from the timing of payments at the end of February 2017 and by the cost of sales and operating expenses in May 2016 being \$3.7 million higher than February 2017.

Cash Flow from Investing Activities

Net cash used in investing activities for the nine months ended February 26, 2017 was \$9.4 million compared to \$26.9 million for the same period last year. The primary uses of cash in investing activities during the first nine months of fiscal year 2017 were for the purchase of \$9.5 million of equipment, primarily to support the growth of the Apio Packaged Fresh Vegetables and Lifecore businesses.

Cash Flow from Financing Activities

Net cash used in financing activities for the nine months ended February 26, 2017 was \$10.9 million compared to \$14.5 million of net cash provided by financing activities for the same period last year. The net cash used in financing activities during the first nine months of fiscal year 2017 was primarily due to \$56.0 million of payments on the Company's long-term debt as a result of refinancing all of the Company's debt during the second quarter of fiscal year 2017 and a \$3.5 million net payments on the Company's line of credit, partially offset by \$50 million of proceeds from the Company refinancing its long-term debt.

Capital Expenditures

During the nine months ended February 26, 2017, Landec purchased equipment to support the growth of the Apio Packaged Fresh Vegetables and Lifecore businesses. These expenditures represented the majority of the \$9.5 million of capital expenditures in the period.

Debt

The Company had entered into various loan agreements, primarily with banks, in connection with the acquisition of GreenLine Holding Company in April 2012 and to finance the capacity expansion of its operations, new product development, and other innovation efforts. These individual loans were extinguished during the three months ended November 27, 2016 and replaced with a term loan and revolving commitment.

See Note 7 – Debt of the Notes to Consolidated Financial Statements for further discussion of the Company's debt arrangements.

Landec believes that its cash from operations, along with existing cash and cash equivalents will be sufficient to finance its operational and capital requirements for at least the next twelve months.

Item 3. *Quantitative and Qualitative Disclosures About Market Risk*

There have been no material changes to the Company's market risk during the first nine months of fiscal year 2017.

Item 4. *Controls and Procedures*

Evaluation of Disclosure Controls and Procedures

Management evaluated, with participation of the Chief Executive Officer and the Chief Financial Officer, the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company's disclosure controls and procedures are effective in ensuring that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission, and are effective in providing reasonable assurance that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in internal controls over financial reporting during the fiscal quarter ended February 26, 2017 that have materially affected, or are reasonably likely to materially affect, internal controls over financial reporting.

Part II. Other Information

Item 1. Legal Proceedings

In the ordinary course of business, the Company is involved in various legal proceedings and claims.

The Company makes a provision for a liability relating to legal matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These provisions are reviewed at least each fiscal quarter and adjusted to reflect the impacts of negotiations, estimated settlements, legal rulings, advice of legal counsel, and other information and events pertaining to a particular matter. Legal fees are expensed in the period in which they are incurred.

Apio has been the target of a union organizing campaign which has included two unsuccessful attempts to unionize Apio's Guadalupe, California processing plant. The campaign has involved a union and over 100 former and current employees of Pacific Harvest, Inc. and Rancho Harvest, Inc. (collectively "Pacific Harvest"), Apio's plant labor contractors, bringing legal actions before various state and federal agencies, the California Superior Court, and initiating over 100 individual arbitrations against Apio and Pacific Harvest.

The Company has been a co-defendant in civil actions and administrative actions involving claims filed by current and past employees of Pacific Harvest. The legal actions consist of three main types of claims: (1) Unfair Labor Practice claims ("ULPs") before the National Labor Relations Board ("NLRB"), (2) discrimination/wrongful termination claims before state and federal agencies and in individual arbitrations, and (3) wage and hour claims as part of two Private Attorney General Act ("PAGA") cases in state court and in over 100 individual arbitrations.

A settlement of the ULPs among a union, Apio, and Pacific Harvest that were pending before the NLRB was approved on December 27, 2016 for \$310,000. Apio was responsible for half of this settlement, or \$155,000. Concerning the discrimination/wrongful termination claims and the wage and hour claims, on February 23, 2017, the parties agreed in principle to a class action settlement which covers all non-exempt employees of Pacific Harvest working at Apio's Guadalupe, California processing facility. This settlement remains subject to all of the plaintiffs executing the settlement agreement, and the settlement agreement being approved by the Santa Barbara County Superior Court. Under the settlement agreement, the plaintiffs will be paid \$6.0 million in three installments: \$2.4 million in April 2017, \$1.8 million in November 2017, and \$1.8 million in July 2018. The Company and Pacific Harvest have each agreed to pay one half of the settlement.

Based on the initial number of asserted claims and the initial length of time covered by the claims, Apio had recorded a legal settlement contingency accrual of \$1.3 million as of November 27, 2016, which the Company believed at that time was sufficient to resolve its share of the costs of the legal actions prior to the broader settlement ultimately reached; which significantly increased the number of potential claims and the number of past years covered in the final settlement, thus resulting in the higher final settlement amount.

During the three and nine months ended February 26, 2017, the Company recorded a legal settlement charge of \$2.1 million and \$2.6 million, respectively, relating to these actions. As of February 26, 2017, the Company had accrued \$3.2 million relating to these actions, which is included in Other accrued liabilities in the accompanying Consolidated Balance Sheet.

Item 1A. Risk Factors

There have been no significant changes to the Company's risk factors which are included and described in the Form10-K for the fiscal year ended May 29, 2016 filed with the Securities and Exchange Commission on July 29, 2016.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of equity securities or shares repurchased by the Company during the fiscal quarter ended on February 26, 2017.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable

Item 5. Other Information

None.

-28-

Item 6. Exhibits

Exhibit Number	Exhibit Title
31.1+	CEO Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
31.2+	CFO Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
32.1+	CEO Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
32.2+	CFO Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.

101.INS** XBRL Instance

101.SCH** XBRL Taxonomy Extension Schema

101.CAL** XBRL Taxonomy Extension Calculation

101.DEF** XBRL Taxonomy Extension Definition

101.LAB** XBRL Taxonomy Extension Labels

101.PRE** XBRL Taxonomy Extension Presentation

+ Filed herewith.

** XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

LANDEC
CORPORATION

By: /s/ Gregory S. Skinner
Gregory S. Skinner
Vice President Finance
and Chief Financial
Officer
(Principal Financial
and Accounting
Officer)

Date: April 6, 2017